Company Overview - BioCardia, Inc. is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases [2] - The company is headquartered in Sunnyvale, California and focuses on developing biotherapeutic platforms, including CardiAMP autologous and CardiALLO™ allogeneic cell therapies [2] Financial Reporting - BioCardia will report its financial results for the year ended December 31, 2024 on March 26, 2025 [1] - A corporate update conference call is scheduled for March 31, 2025, following a presentation at the American College of Cardiology 2025 Scientific Sessions [1] Clinical Development - BioCardia has three cardiac clinical stage product candidates in development, enabled by its Helix™ biotherapeutic delivery and Morph vascular navigation product platforms [2] - The company will present results from the CardiAMP-HF Trial, a double-blind, randomized controlled trial of an autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF), on March 30, 2025 [1]
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025